Clinical Trials Browser

SNX-5422 × Lymphoid × Clear all

NCT02914327 2018-07-30

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00644072 2017-07-02

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

Phase 1 Completed

Lymphoma, Neoplasms